BSX - Boston Scientific Corporation

NYSE - NYSE Delayed Price. Currency in USD
30.31
-0.09 (-0.30%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close30.40
Open30.38
Bid29.45 x 1100
Ask0.00 x 1100
Day's Range30.24 - 30.49
52 Week Range24.54 - 30.84
Volume2,685,722
Avg. Volume6,975,510
Market Cap41.813B
Beta0.99
PE Ratio (TTM)398.82
EPS (TTM)0.08
Earnings DateJul 25, 2018 - Jul 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.76
Trade prices are not sourced from all markets
  • Boston Scientific (BSX) Up 3.5% Since Earnings Report: Can It Continue?
    Zacksyesterday

    Boston Scientific (BSX) Up 3.5% Since Earnings Report: Can It Continue?

    Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Veeva Systems (VEEV) Beats Q1 Earnings Estimates, Raises View
    Zacks2 days ago

    Veeva Systems (VEEV) Beats Q1 Earnings Estimates, Raises View

    Solid performance in Subscription revenues is a key catalyst for Veeva Systems (VEEV) in Q1.

  • Devices reduce trips to doctor’s office
    American City Business Journals2 days ago

    Devices reduce trips to doctor’s office

    The virtual world has changed the patient-doctor relationship as men and women ranging from millennials to seniors explore options in health care outside the traditional doctor’s office or hospital.

  • Here's Why You Should Buy Boston Scientific (BSX) Stock Now
    Zacks2 days ago

    Here's Why You Should Buy Boston Scientific (BSX) Stock Now

    Boston Scientific's (BSX) inorganic expansion plan bodes well for operational growth.

  • Zacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and Celanese
    Zacks10 days ago

    Zacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and Celanese

    Zacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and Celanese

  • PR Newswire11 days ago

    Boston Scientific Announces Schedule of Presentations at EuroPCR 2018

    MARLBOROUGH, Mass. , May 16, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of key presentations, including two late-breaking clinical trials, that will be ...

  • 5 Top ROE Stocks to Buy as U.S.-China Trade Concerns Subside
    InvestorPlace11 days ago

    5 Top ROE Stocks to Buy as U.S.-China Trade Concerns Subside

    The equity markets continued to breathe easy as the U.S.-China trade concerns abated with President Trump pledging support for the beleaguered Chinese telecom firm, ZTE, and the Qualcomm-NXP merger review process getting a roll-on with urgency from the top administration of China. A high ROE ensures that the company is reinvesting its cash at a high rate of return. ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • 5 Top ROE Stocks to Buy as U.S.-China Trade Concerns Subside
    Zacks12 days ago

    5 Top ROE Stocks to Buy as U.S.-China Trade Concerns Subside

    ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • ’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh
    InvestorPlace12 days ago

    ’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh

    This takes a look at the gynecological mesh, how it has affected women it was placed in, and the 48,000 lawsuits concerning it. The first bit of bad publicity for Boston Scientific is what has been happening to the gynecological mesh over time. The report then looks at how Boston Scientific makes the gynecological mesh.

  • Boston Scientific To Participate In 34th Annual Strategic decisions Conference
    PR Newswire13 days ago

    Boston Scientific To Participate In 34th Annual Strategic decisions Conference

    MARLBOROUGH, Mass. , May 14, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 34 th Annual Strategic Decisions Conference on May 31, 2018 in New York . ...

  • PR Newswire15 days ago

    Boston Scientific Announces Real-World Data Demonstrating Success Of SMART Pass On The S-ICD System

    MARLBOROUGH, Mass., May 11, 2018 /PRNewswire/ -- Boston Scientific (BSX) today announced results from an analysis of the LATITUDE database which evaluated the successful reduction of inappropriate shocks using the SMART Pass sensing filter in patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The real-world data were presented during a late-breaking clinical trial at Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions in Boston, and demonstrated that when the sensing filter was in use, the rate of inappropriate shocks was reduced to 4.3% at one year.

  • The Wall Street Journal15 days ago

    [$$] Heart Device Procedure Is No Better Than Drug Therapy for Irregular Heartbeat: Study

    An increasingly common cardiovascular procedure using a device made by several medical technology companies was no better than drug therapy at preventing deaths, strokes and certain other complications, a new study found. The outcome of the trial raises questions about the procedure, known as catheter ablation, to treat patients with atrial fibrillation. Abbott Laboratories, Johnson & Johnson, Medtronic PLC and Boston Scientific Corp. make the device used in the procedure.

  • Will Boston Scientific Corporation (NYSE:BSX) Continue To Underperform Its Industry?
    Simply Wall St.17 days ago

    Will Boston Scientific Corporation (NYSE:BSX) Continue To Underperform Its Industry?

    Boston Scientific Corporation (NYSE:BSX) delivered a less impressive 1.59% ROE over the past year, compared to the 11.43% return generated by its industry. Though BSX’s recent performance is underwhelming, itRead More...

  • A Look at Abbott Laboratories’ Valuation Multiples
    Market Realist19 days ago

    A Look at Abbott Laboratories’ Valuation Multiples

    On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.

  • Boston Scientific To Participate In Bank of America Merrill Lynch 2018 Health Care Conference
    PR Newswire19 days ago

    Boston Scientific To Participate In Bank of America Merrill Lynch 2018 Health Care Conference

    MARLBOROUGH, Mass. , May 7, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2018 Health Care Conference on May 16, 2018 in ...

  • New Product Launches Drive ABT’s Medical Device Business
    Market Realist23 days ago

    New Product Launches Drive ABT’s Medical Device Business

    (Continued from Prior Part)ABT’s Medical Device business In 1Q18, Abbott Laboratories (ABT) registered sales of $7.4 billion, representing YoY (year-over-year) growth of ~16.7%. The company’s Medical Device segment registered strong growth and contributed ~37.0% to the company’s total sales, the highest of all four of its segments.  ABT’s Medical Device segment sales came in at ~$2.7 billion in 1Q18. On a reported basis, the segment’s sales growth was ~14.6% on a YoY basis. However, on an organic basis, the segment’s sales increased ~9.4%. ...

  • ABT’s Medical Devices Business: A Key Growth Driver
    Market Realist23 days ago

    ABT’s Medical Devices Business: A Key Growth Driver

    On April 18, Abbott Laboratories (ABT) released its 1Q18 earnings results. The company registered revenues of $7.4 billion, which represents YoY (year-over-year) growth of ~16.7%. These sales results exceeded analysts’ estimates. 

  • ABT’s Recent Stock Slump: What’s behind the Decline?
    Market Realist23 days ago

    ABT’s Recent Stock Slump: What’s behind the Decline?

    On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.

  • Analysts’ Recent Recommendations and Target Price for ABT Stock
    Market Realist23 days ago

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.

  • Boston Scientific Closes NxThera Acquisition
    PR Newswire27 days ago

    Boston Scientific Closes NxThera Acquisition

    MARLBOROUGH, Mass., April 30, 2018 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced the close of its acquisition of NxThera. The company developed the Rezūm® system, a minimally invasive therapy (MIT) for patients with symptomatic benign prostatic hyperplasia (BPH). With the completion of the acquisition, NxThera will become part of the Boston Scientific Urology and Pelvic Health business.

  • Thermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up
    Market Realistlast month

    Thermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up

    On April 25, Thermo Fisher Scientific (TMO) announced its earnings results for 1Q18, which ended on March 31. Its revenues grew ~23% to ~$5.9 billion YoY (year-over-year). The sales results came in ahead of analysts’ estimate of ~$5.6 billion.

  • Boston Scientific Raised Its 2018 Outlook
    Market Realistlast month

    Boston Scientific Raised Its 2018 Outlook

    On April 25, Boston Scientific announced its 1Q18 earnings results. Boston Scientific’s results exceeded analysts’ estimates and the company guidance. During the earnings release, Boston Scientific updated its outlook for fiscal 2018. The company expects to register fiscal 2018 sales of $9.75 billion–$9.9 billion. The EPS (earnings per share) in fiscal 2018 is expected to be $1.37–$1.41.

  • BP, Boston Scientific, Madison Square Garden & Dillard's
    CNBC Videos9 days ago

    BP, Boston Scientific, Madison Square Garden & Dillard's

    The "Halftime Report" traders give their top stocks to watch for the second half

  • MARKETS: Stocks are selling off on the ISM miss, which also reveals problems in the factory sector
    Yahoo Finance Video25 days ago

    MARKETS: Stocks are selling off on the ISM miss, which also reveals problems in the factory sector

    Yahoo Finance's Jared Blikre joins Seana Smith from the New York Stock Exchange to discuss the latest market moves.